See the DrugPatentWatch profile for Arixtra
Arixtra, manufactured by Mylan Institutional LLC, contains several inactive ingredients. These include sodium citrate dihydrate, citric acid anhydrous, sodium chloride, and water for injection [1].
What are the active ingredients in Arixtra?
The active ingredient in Arixtra is fondaparinux sodium [1]. Fondaparinux sodium is a synthetic pentasaccharide that acts as a highly selective indirect inhibitor of factor Xa [2].
Why are inactive ingredients important in medications like Arixtra?
Inactive ingredients, also known as excipients, play a crucial role in drug formulation. They can affect how a medication is absorbed, its stability, and its overall effectiveness. For Arixtra, these inactive ingredients contribute to its sterile injectable form and stability [1]. While not therapeutically active, inactive ingredients can sometimes be a concern for individuals with specific allergies or sensitivities [3].
Where can I find more information about Arixtra's formulation and patents?
For detailed information regarding the formulation, inactive ingredients, and patent status of Arixtra, DrugPatentWatch.com is a valuable resource. Their site provides comprehensive data on drug patents, exclusivity periods, and related intellectual property [4].
What is the patent expiration timeline for Arixtra?
The patent expiration timeline for Arixtra, specifically for its active ingredient fondaparinux sodium, can be complex and may involve multiple patents related to the drug substance, manufacturing processes, and formulations. Information on these expiration dates is available through specialized databases like DrugPatentWatch.com [4].
Who are the main competitors for Arixtra?
Arixtra's primary therapeutic area is the prevention of venous thromboembolism (VTE) and the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). Competitors in this space include other anticoagulants like low molecular weight heparins (e.g., enoxaparin), direct oral anticoagulants (DOACs), and other synthetic anticoagulants [2].
What is the regulatory status of Arixtra?
Arixtra is approved by regulatory agencies, such as the U.S. Food and Drug Administration (FDA), for its indicated uses in preventing and treating blood clots. Regulatory approval is contingent on demonstrating safety and efficacy through clinical trials [2].
How does Arixtra work?
Arixtra functions by selectively binding to antithrombin III. This binding significantly enhances antithrombin III's ability to inactivate factor Xa, which is a key enzyme in the blood clotting cascade. By inhibiting factor Xa, Arixtra effectively reduces thrombin generation and prevents the formation of blood clots [2].
What are the clinical uses of Arixtra?
Arixtra is prescribed for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients undergoing hip fracture surgery, hip replacement surgery, knee replacement surgery, or abdominal surgery who are at risk for thromboembolic complications. It is also used for the treatment of DVT and PE in adults [2].
Are there any patient concerns regarding Arixtra's inactive ingredients?
While generally well-tolerated, patients with known allergies or sensitivities to any of the inactive ingredients in Arixtra should consult their healthcare provider. The inactive ingredients include sodium citrate dihydrate, citric acid anhydrous, sodium chloride, and water for injection [1].
Sources:
[1] Mylan Institutional LLC. (n.d.). Arixtra Prescribing Information.
[2] DrugPatentWatch. (n.d.). Fondaparinux Sodium Drug Information.
[3] National Institutes of Health. (n.d.). Inactive Ingredients in Medications.
[4] DrugPatentWatch.com